Allergy & Immunology

Tralokinumab effective and well tolerated in multimorbid adults with moderate-to-severe atopic dermatitis

In 21 adults with high multimorbidity treated with tralokinumab 300 mg Q2W, mean EASI fell from 19.3 to 3.45 over a mean 24.6 months follow-up. Pruritus NRS declined from 7 to 2, with ~70% achieving EASI ≤3 and 50% reaching EASI 0–1. No tumor progression, infection reactivation, major cardiovascular events, or severe adverse events were reported in this series. These real-world findings support IL-13 blockade as an option for patients often excluded from trials, but the study is small and retrospective. 1

Peripheral eosinophil dynamics predict outcomes and irAE risk during ICI therapy in NSCLC

In 316 patients with unresectable stage III–IV NSCLC, increases in absolute eosinophil count and eosinophil percent by cycle 4 independently associated with improved overall survival. Cycle 4 AEC > 0.22×10^9/L and E% > 2.60% were linked to better OS and PFS in this cohort. Higher AECs at cycles 2 and 4 and early increases from baseline to cycle 2 correlated with higher immune-related adverse event risk. Baseline eosinophil measures did not predict irAEs; these markers require prospective validation before altering management. 2

Food insecurity commonly complicates pediatric food-allergy management

This scoping review included 56 articles, mainly from the US and Canada, mapping prevalence, quality-of-life impacts, and social determinants. Food insecurity was linked to worse food-allergy–related quality of life and potential increases in adverse event risk. No clinical standards or guidelines were identified to address food insecurity in pediatric food allergy. Clinicians should screen for food insecurity and connect families with social and nutritional resources given evidence gaps. 3